Physician perceptions, attitudes, and strategies towards implementing guideline‐directed medical therapy in heart failure with reduced ejection fraction. A survey of the Heart Failure Association of the ESC and the ESC Council for Cardiology Practice
Gianluigi Savarese,Felix Lindberg,Ruxandra M. Christodorescu,Marc Ferrini,Thomas Kumler,Konstantinos Toutoutzas,Giuseppe Dattilo,Antoni Bayes‐Genis,Brenda Moura,Offer Amir,Mark C. Petrie,Petar Seferovic,Ovidiu Chioncel,Marco Metra,Andrew J.S. Coats,Giuseppe M.C. Rosano
DOI: https://doi.org/10.1002/ejhf.3214
2024-03-23
European Journal of Heart Failure
Abstract:Physician perceptions of current state of and strategies to improve implementation of guideline‐directed medical therapy (GDMT) in patients with heart failure with reduced ejection fraction (HFrEF). ARNI, angiotensin receptor–neprilysin inhibitor; BB, beta‐blocker; ESC, European Society of Cardiology; HFA, Heart Failure Association; MRA, mineralocorticoid receptor antagonist; RASi, renin–angiotensin system inhibitor; SGLT2i, sodium–glucose cotransporter 2 inhibitor. Aims Recent guidelines recommend four core drug classes (renin–angiotensin system/angiotensin receptor–neprilysin inhibitor [RASi/ARNi], beta‐blocker, mineralocorticoid receptor antagonist [MRA], and sodium–glucose cotransporter 2 inhibitor [SGLT2i]) for the pharmacological management of heart failure (HF) with reduced ejection fraction (HFrEF). We assessed physicians' perceived (i) comfort with implementing the recent HFrEF guideline recommendations; (ii) status of guideline‐directed medical therapy (GDMT) implementation; (iii) use of different GDMT sequencing strategies; and (iv) barriers and strategies for achieving implementation. Methods and results A 26‐question survey was disseminated via bulletin, e‐mail and social channels directed to physicians with an interest in HF. Of 432 respondents representing 91 countries, 36% were female, 52% were aged 90% of patients with HFrEF without contraindications received quadruple therapy. The time required to initiate quadruple therapy was estimated at 1–2 weeks by 34% of respondents, 1 month by 36%, 3 months by 24%, and ≥6 months by 6%. The average respondent favoured traditional drug sequencing strategies (RASi/ARNi with/followed by beta‐blocker, and then MRA with/followed by SGLT2i) over simultaneous initiation or SGLT2i‐first sequences. The most frequently perceived clinical barriers to implementation were hypotension (70%), creatinine increase (47%), hyperkalaemia (45%) and patient adherence (42%). Conclusions Although comfort with implementing all four core drug classes in patients with HFrEF was high among physicians, a majority estimated implementation of GDMT in HFrEF to be low. We identified several important perceived clinical and non‐clinical barriers that can be targeted to improve implementation.
cardiac & cardiovascular systems